Stock Yards Bank & Trust Co. Sells 4,350 Shares of Danaher Co. (NYSE:DHR)

Stock Yards Bank & Trust Co. reduced its stake in Danaher Co. (NYSE:DHR - Free Report) by 3.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 112,146 shares of the conglomerate's stock after selling 4,350 shares during the period. Stock Yards Bank & Trust Co.'s holdings in Danaher were worth $31,179,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. CarsonAllaria Wealth Management Ltd. bought a new stake in Danaher during the 2nd quarter valued at $25,000. nVerses Capital LLC bought a new position in shares of Danaher during the second quarter valued at about $25,000. Teachers Insurance & Annuity Association of America purchased a new stake in shares of Danaher during the third quarter worth about $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the third quarter worth about $40,000. Finally, FSA Wealth Management LLC purchased a new position in Danaher during the 3rd quarter valued at about $50,000. Institutional investors own 79.05% of the company's stock.

Danaher Stock Down 0.4 %

Danaher stock traded down $0.90 during trading hours on Thursday, hitting $234.50. The stock had a trading volume of 3,995,293 shares, compared to its average volume of 2,786,486. The stock's 50-day moving average price is $248.34 and its 200-day moving average price is $257.78. Danaher Co. has a 12-month low of $219.15 and a 12-month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $169.37 billion, a P/E ratio of 44.93, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analysts' expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm's quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.02 EPS. Equities research analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend is Friday, December 27th. Danaher's dividend payout ratio (DPR) is 20.61%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on DHR shares. Robert W. Baird cut their price objective on Danaher from $278.00 to $277.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 23rd. Evercore ISI lifted their price target on shares of Danaher from $275.00 to $278.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. TD Cowen upped their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a "buy" rating in a report on Wednesday, October 23rd. Raymond James cut their target price on shares of Danaher from $310.00 to $300.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 23rd. Finally, Wolfe Research upgraded shares of Danaher from a "peer perform" rating to an "outperform" rating and set a $285.00 price objective for the company in a report on Thursday, October 31st. Six research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.